BEDFORD, Mass.–(BUSINESS WIRE)–Anika
Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company
plans to issue its fourth-quarter and full-year 2018 financial results
after the close of the market on Thursday, February 21, 2019 and hold
its investor conference call on the same day, Thursday, February 21,
2019, at 5:00 p.m. ET to discuss its financial results, business
highlights, and outlook.
The conference call can be accessed by dialing 1-855-468-0611 (toll-free
domestic) or 1-484-756-4332 (international). A live audio webcast will
be available in the “Investor
Relations” section of Anika’s website, www.anikatherapeutics.com.
An accompanying slide presentation also can be accessed via the Anika
Therapeutics website. The call will be archived and accessible on the
same website shortly after its conclusion.
About Anika Therapeutics, Inc.
Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic
and regenerative medicines company based in Bedford,
Massachusetts. Anika is committed to improving the lives of patients
with degenerative orthopedic diseases and traumatic conditions with
clinically meaningful therapies along the continuum of care, from
palliative pain management to regenerative tissue repair. The Company
has over two decades of global expertise developing, manufacturing, and
commercializing more than 20 products based on its proprietary hyaluronic
acid (HA) technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC®,
alleviate pain and restore joint function by replenishing depleted HA,
a solid HA-based scaffold to aid cartilage repair and regeneration. For
more information about Anika, please visit www.anikatherapeutics.com.
For Investor Inquiries:
Anika Therapeutics, Inc.
Chief Financial Officer
Sonal Vasudev, 917-523-1418